Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial - Thatcher, N; Hirsch, F R; Luft, A V (Lancet Oncol, 2015)
et al.